The news about remdesivir, the investigational anti-viral drug that has shown early promise in the fight against COVID-19, keeps getting better. This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.

The National Institute of Allergy & Infectious Diseases (NIAID) has founded a new clinical trials network focused on enrolling volunteers in clinical trials for COVID-19 vaccines and monoclonal antibodies.

The latest funding round came hard on the heels of $75 million the company raised in March, giving the company a total of $177 million raised in the first half of 2020.

Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

The U.S. Food and Drug Administration issued a Complete Response Letter to Merck and Eisai over their Lenvima and Keytruda combination for first-line treatment of unresectable hepatocellular carcinoma (HCC).

San Mateo, Calif.-based Tranquis will initially focus its research on orphan diseases such as Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).

Diagnostics and therapeutics for Alzheimer’s disease are on the verge of becoming mainstream medicine. It’s about time, too.

Low-dose radiation therapy seems to improve outcomes for COVID-19 patients. At least a dozen clinical trials are underway throughout the world to further explore the benefits.

Forbion, a European life sciences venture capital firm, announced today that it had closed its Forbion Growth Opportunities Fund at $208 million.

An important line of defence in the fight against the new corona virus SARS-CoV-2 is the formation of neutralising antibodies. These can eliminate the intruders and have great potential to be used for prevention and treatment of SARS-CoV-2 infection. A team of researchers led by Prof. Florian Klein (Cologne University Hospital) and the German Center for Infection Research (DZIF) has further elucidated how these antibodies develop and has isolated potent SARS-CoV-2 neutralizing antibodies.

Foghorn Therapeutics entered into a strategic collaboration with Merck to leverage Foghorn’s Gene Traffic Control platform for cancer therapies.

ViiV Healthcare announced an injection of cabotegravir given every two months was 66% more effective at preventing HIV infection when compared to Gilead Sciences’ Truvada, according to the final analysis of the HPTN-083 study.

On Tuesday, the White House notified Congress and the United Nations of the decision. However, the withdrawal will not be immediate.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.

What if you could get one vaccine that protects you against a wide spectrum of viruses, even viruses we haven’t discovered yet?

The submission was completed with ongoing collaboration with the FDA and include data from the Phase III EMERGE and ENGAGE trials, as well as the Phase Ib PRIME study. Biogen has also requested Priority Review.

Kiadis Pharma, based in Amsterdam, The Netherlands, licensed a previously undisclosed K-NK0004 program to Paris-based Sanofi.

Evive Biotech announced today that its Phase III study investigating F-627 to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients has met its primary and secondary endpoints.

Through the partnership, Takeda will have access to Twist’s “Library of Libraries,” a large phage display library created using precisely defined synthetic DNA sequences to discover unique antibodies to important therapeutic targets including GPCRs.

What factors do you think affect burnout? Do you think some industries are more prone to burnout than others?